Business
Multi-year supply agreement with BMS
Oxford Biomedica PLC has signed a new multi-year Commercial Supply Agreement with Bristol Myers Squibb to become the commercial manufacturer of lentiviral vectors for BMS' CAR-T programmes, with an initial five-year term and an option to extend. This expanded partnership, building on a previous agreement from March 2020, is expected to commence commercial manufacturing in 2026, subject to regulatory approval, and will take place at OXB's facilities in Oxford, UK, and Durham, NC, US. The agreement is anticipated to generate significant multi-year revenue, supporting the company's medium-term financial guidance and demonstrating the successful execution of its cell and gene therapy CDMO strategy. Disclaimer*
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n\n \n \nOXB Signs New Multi-Year Commercial Supply Agreement with Bristol Myers Squibb\n- OXB to become commercial manufacturer of lentiviral vectors for Bristol Myers Squibb (BMS) CAR-T programmes\n- Multi-year agreement with five-year initial term and option to extend\n \nOxford, UK - 4 February 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has expanded its strategic partnership with Bristol Myers Squibb (\"BMS\") (NYSE: BMY), signing a new Commercial Supply Agreement (CSA) for the manufacture and supply of lentiviral vectors for BMS' CAR-T programmes.\nThis expanded partnership builds on the existing relationship with Bristol Myers Squibb, originally announced in March 2020.\nUnder the new agreement, OXB is expected to commence commercial manufacturing in 2026, subject to regulatory approval of the relevant CAR-T products. Manufacturing will take place at OXB's facilities in Oxford, UK, and Durham NC, US.\nThe CSA is expected to generate meaningful multi-year revenue and supports the Company's existing medium-term financial guidance, demonstrating further successful execution of OXB's focused cell and gene therapy CDMO strategy.\n \nDr Sebastien Ribault, Chief Business Officer of OXB, commented: \"The transition from clinical to commercial manufacturing with BMS marks an important milestone for both companies. Having supported these potentially life-saving CAR-T programmes through development, we are confident in their commercial success and look forward to continuing our partnership with BMS. This long-term commitment underlines our excellent revenue visibility, reflects our strong track record, and demonstrates continued successful execution of our strategy as a leading cell and gene therapy CDMO.\"\nChris Holt, Vice President, Cell Therapy Vector and External Manufacturing Operations, Bristol Myers Squibb, added: \"OXB has been an excellent manufacturing partner supporting our CAR-T cell therapy programmes through clinical development. This expanded agreement reflects our confidence in their world-class capabilities and proven expertise in delivering high-quality, commercial-grade viral vectors. As we advance our innovative CAR-T therapies toward patients, this strategic partnership ensures ...